Related references
Note: Only part of the references are listed.COMPASS identifies T-cell subsets correlated with clinical outcomes
Lin Lin et al.
NATURE BIOTECHNOLOGY (2015)
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Himal Lal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen
Joseph G. Jardine et al.
SCIENCE (2015)
Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein
Jia Chen et al.
SCIENCE (2015)
HIV-1 neutralizing antibodies induced by native-like envelope trimers
Rogier W. Sanders et al.
SCIENCE (2015)
Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys
Dan H. Barouch et al.
SCIENCE (2015)
Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes
Mohammed Asmal et al.
VIROLOGY (2015)
Generation and Evaluation of Clade C Simian-Human Immunodeficiency Virus Challenge Stocks
Hui-Wen Chang et al.
JOURNAL OF VIROLOGY (2015)
Fcγ Receptor Variability in the South African Population - Will this Impact HVTN097 Vaccine Efficacy?
Ria Lassauniere et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2014)
Ten years after Dublin: principal trends in HIV surveillance in the EU/EEA, 2004 to 2013
A. Pharris et al.
EUROSURVEILLANCE (2014)
Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved
Kevin Wiehe et al.
IMMUNITY (2014)
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial
Shuying S. Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Live Simian Immunodeficiency Virus Vaccine Correlate of Protection: Immune Complex-Inhibitory Fc Receptor Interactions That Reduce Target Cell Availability
Anthony J. Smith et al.
JOURNAL OF IMMUNOLOGY (2014)
HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities
Justin Pollara et al.
JOURNAL OF VIROLOGY (2014)
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
Sung-Youl Ko et al.
NATURE (2014)
Ending AIDS - Is an HIV Vaccine Necessary?
Anthony S. Fauci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection
Susan Zolla-Pazner et al.
PLOS ONE (2014)
Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development
George K. Lewis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Host Controls of HIV Neutralizing Antibodies
Barton F. Haynes et al.
SCIENCE (2014)
Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines
Amy W. Chung et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor
Amarendra Pegu et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination
Nicole L. Yates et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses
Susan Zolla-Pazner et al.
EBIOMEDICINE (2014)
Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys
Dan H. Barouch et al.
CELL (2013)
Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2
Hua-Xin Liao et al.
IMMUNITY (2013)
Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion
S. Munir Alam et al.
JOURNAL OF VIROLOGY (2013)
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Scott M. Hammer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
Raphael Gottardo et al.
PLOS ONE (2013)
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
Georgia D. Tomaras et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa
Frank Tanser et al.
SCIENCE (2013)
Nonreplicating vectors in HIV vaccines
Jennifer A. Johnson et al.
CURRENT OPINION IN HIV AND AIDS (2013)
The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120
Nicos Karasavvas et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2012)
Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
David C. Montefiori et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family
Mattia Bonsignori et al.
JOURNAL OF VIROLOGY (2012)
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
Morgane Rolland et al.
NATURE (2012)
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
Dan H. Barouch et al.
NATURE (2012)
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Cross-Clade HIV-1 Neutralizing Antibodies Induced with V3-Scaffold Protein Immunogens following Priming with gp120 DNA
Susan Zolla-Pazner et al.
JOURNAL OF VIROLOGY (2011)
Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01
Yuxing Li et al.
JOURNAL OF VIROLOGY (2011)
HIV Vaccine Development - Improving on Natural Immunity
Margaret I. Johnston et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
HIV-1 Vaccines and Adaptive Trial Designs
Lawrence Corey et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Xueling Wu et al.
SCIENCE (2010)
Poxvirus vector-based HIV vaccines
Giuseppe Pantaleo et al.
CURRENT OPINION IN HIV AND AIDS (2010)
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
HIV-1-specific antibody responses during acute and chronic HIV-1 infection
Georgia D. Tomaras et al.
CURRENT OPINION IN HIV AND AIDS (2009)
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
M. Juliana McElrath et al.
LANCET (2008)
EV01:: A phase I trial in healthy HIV negative volunteers to evaluate a clade CHIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium
Pierre-Alexandre Bart et al.
VACCINE (2008)
Fc receptor but not complement binding is important in antibody protection against HIV
Ann J. Hessell et al.
NATURE (2007)
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
Punnee Pitisuttithum et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge
Ruth H. Florese et al.
JOURNAL OF IMMUNOLOGY (2006)
A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens
M Singh et al.
VACCINE (2006)
Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults
S Nitayaphan et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia
JM Binley et al.
VIROLOGY (2000)